How to Submit
Browse
Events
Communities
About

Anti-Breast Cancer Stem Cell Activity of Titanocene Complexes of Non-Steroidal Anti-Inflammatory Drugs

03 June 2025, Version 1
Working Paper
This content is an early or alternative research output and has not been peer-reviewed by Cambridge University Press at the time of posting.

Abstract

Titanocene(IV)-NSAID complexes Cp2Ti(mefenamate)2 (4) and Cp2Ti(flufenamate)2 (5) show enhanced redox stability and potent cytotoxicity against breast cancer stem cells (CSCs), with 5 rivaling salinomycin and cisplatin. Complex 5 induces DNA damage and apoptosis, and its nanoparticle encapsulation improves biocompatibility. This is the first report targeting breast CSCs with titanocene-based metallodrugs.

Keywords

titanocenes
cancer stem cells
polymeric nanoparticles

Supplementary materials

Title
Description
Actions
Title
Electronic Supplementary Information
Description
Experimental details. Additional synthesis and characterisation data (NMR, MS, CV, IR, XRD). Additional biological data.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting and Discussion Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Jun 03, 2025 Version 1

Metrics

646
152
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv-2025-0bclj
D O I: 10.26434/chemrxiv-2025-0bclj [opens in a new tab]

Funding

Engineering and Physical Sciences Research Council
EP/Y002695/1
Engineering and Physical Sciences Research Council
EP/Y002695/1
Engineering and Physical Sciences Research Council
EP/V034766/1

Author’s competing interest statement

The author(s) have declared they have no conflict of interest with regard to this content

Ethics

The author(s) have declared ethics committee/IRB approval is not relevant to this content

Share